1274 NONINVASIVE TEST FOR DIAGNOSIS AND AGGRESSIVENESS ASSESSMENT OF BLADDER CANCER: VALIDATION STUDY

Table 2: Bladder Cancers Detected Placebo Vitamin E Selenium Combination Years of Follow-up (median, IQR) 7.0 (6.1, 8.0) 7.0 (6.0, 8.0) 7.0 (6.0, 8.0) 7.0 (6.0, 8.0) No. of Bladder Cancers 53 56 60 55 Stage CIS 3 4 4 3 TA 32 26 30 36 T1 10 18 19 7 T1 6 6 6 7 Unknown 2 2 1 2 Grade Well differentiated 21 18 23 29 Moderately differentiated 9 7 10 5 Poorly differentiated 22 29 26 19 Unknown 1 2 1 2 N-stage N0 3 2 3 5 N1 3 2 1 0 NX 47 52 56 50 M-stage M0 2 0 3 3 M1 3 3 0 1 MX 48 53 57 51 Histology Urothelial cell 51 53 59 50 Squamous cell 1 0 1 0 Adenocarcinoma 0 0 0 1 Small cell 0 1 0 0 Other/Unknown 1 2 0 4 Deaths (cause) Bladder cancer 6 6 3 3 Other cause 5 3 4 5 Source of Funding: This work was supported in part by Public Health Service Cooperative Agreement grant CA37429 awarded by the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, and in part by the National Center for Complementary and Alternative Medicine (National Institutes of Health). Study agents and packaging were provided by Perrigo Company (Allegan, Michigan), Sabinsa Corporation (Piscataway, New Jersey), Tishcon Corporation (Westbury, New York), and DSM Nutritional Products Inc. (Parsipanny, New Jersey).